{"id":1984,"date":"2024-04-01T12:02:16","date_gmt":"2024-04-01T12:02:16","guid":{"rendered":"https:\/\/devm.kyowakirininternational.com\/?page_id=1984"},"modified":"2024-09-26T11:08:29","modified_gmt":"2024-09-26T10:08:29","slug":"global-reporting","status":"publish","type":"page","link":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/","title":{"rendered":"Global Reporting"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” background_color=”#FFFFFF” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” header_2_font=”|700|||||||” header_2_text_color=”#ea5504″ global_colors_info=”{}”]<\/p>\n

Reporting and Contact Us<\/h2>\n

REPORTING A SAFETY CONCERN<\/strong><\/p>\n

Kyowa Kirin takes patient safety seriously. We routinely monitor information from multiple sources regarding the safety of our products in order to take any necessary actions. If you would like to report a possible side effect of a Kyowa Kirin product, please provide any relevant information you have about the side effect and if possible please include the following information:<\/p>\n

1. The initials of the person who experienced the possible side effect and\/or other identifiers, such as gender or date of birth
2. The contact information of the person reporting the issue
3. A description of the side effect, such as the signs and symptoms experienced, date the side effect started, and the outcome of the side effect
4. The name of the Kyowa Kirin product and date the person who experienced the side effect began taking it<\/p>\n

Please select your country to contact us and\/or report a safety concern<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_accordion closed_toggle_text_color=”#FFFFFF” closed_toggle_background_color=”#ea5504″ icon_color=”#000000″ module_class=”pa-accordion” _builder_version=”4.26.1″ _module_preset=”default” toggle_font=”|700|||||||” background_color=”RGBA(255,255,255,0)” hover_enabled=”0″ border_radii=”on|10px|10px|10px|10px” global_colors_info=”{}” sticky_enabled=”0″][et_pb_accordion_item title=”Austria” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”on”][et_pb_section global_module=\"1938 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Bahrain” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"1950 \"][\/et_pb_section]<\/p>\n

For reporting any side effects or safety information, please contact us directly via:
\nE-mail: drugsafetygcc@kyowakirin.com
\nHotline: +971 55 187 4456 | Landline: +971 4 581 3700 | Fax: +971 4 581 3776
\nPlease contact the relevant competent authority.[\/et_pb_accordion_item][et_pb_accordion_item title=”Belgium” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2027 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Czech Republic” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Denmark” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2030 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Estonia” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2033 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Finland” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2039 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”France” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2042 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Germany” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n

[et_pb_section global_module=\"2010 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Iceland” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n

[et_pb_section global_module=\"2048 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Ireland” icon_color=”#000000″ _builder_version=”4.25.1″ _module_preset=”default” body_text_color=”#FFFFFF” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n

For Ireland, reporting forms and further information can be found at\u00a0www.hpra.ie<\/a> . By reporting side effects, you can help provide more information on the safety of medicines. Adverse events should also be reported using the contact form below.<\/p>\n

 <\/p>\n

[et_pb_section global_module=\"2045 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Italy” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n

[et_pb_section global_module=\"2051 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Kuwait” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2054 \"][\/et_pb_section]<\/p>\n

For reporting any side effects or safety information, please contact us directly via:
\nE-mail: drugsafetygcc@kyowakirin.com
\nHotline: +971 55 187 4456 | Landline: +971 4 581 3700 | Fax: +971 4 581 3776
\nPlease contact the relevant competent authority.[\/et_pb_accordion_item][et_pb_accordion_item title=”Latvia” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2063 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Lithuania” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2057 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Luxembourg” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” hover_enabled=”0″ global_colors_info=”{}” open=”off” sticky_enabled=”0″]<\/p>\n

[et_pb_section global_module=\"2060 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Netherlands” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2066 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Norway” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2069 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Oman” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” hover_enabled=”0″ global_colors_info=”{}” open=”off” sticky_enabled=”0″][et_pb_section global_module=\"2072 \"][\/et_pb_section]<\/p>\n

For reporting any side effects or safety information, please contact us directly via:
\nE-mail: drugsafetygcc@kyowakirin.com
\nHotline: +971 55 187 4456 | Landline: +971 4 581 3700 | Fax: +971 4 581 3776
\nPlease contact the relevant competent authority.
\n[\/et_pb_accordion_item][et_pb_accordion_item title=”Portugal” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2075 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Qatar” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n[et_pb_section global_module=\"2078 \"][\/et_pb_section]\n

For reporting any side effects or safety information, please contact us directly via:
E-mail: drugsafetygcc@kyowakirin.com
Hotline: +971 55 187 4456 | Landline: +971 4 581 3700 | Fax: +971 4 581 3776
Please contact the relevant competent authority.<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Saudi Arabia” open=”off” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}”]<\/p>\n[et_pb_section global_module=\"2081 \"][\/et_pb_section]\n

For reporting any side effects or safety information, please contact us directly via:
E-mail: drugsafetygcc@kyowakirin.com
Hotline: +971 55 187 4456 | Landline: +971 4 581 3700 | Fax: +971 4 581 3776
Saudi Arabia: – The National Pharmacovigilance and Drug Safety Centre (NPC):
Fax: +966-11-205-7662 | SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https:\/\/ade.sfda.gov.sa\/<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Spain” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2036 \"][\/et_pb_section]
\nWe are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
\nTo do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span>[\/et_pb_accordion_item][et_pb_accordion_item title=”Sweden” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n

[et_pb_section global_module=\"2084 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Switzerland” icon_color=”#000000″ _builder_version=”4.24.3″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”]<\/p>\n

[et_pb_section global_module=\"2020 \"][\/et_pb_section]
We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

Orders<\/strong>
For orders in the Swiss market, click here.<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”United Arab Emirates” icon_color=”#000000″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” open=”off”][et_pb_section global_module=\"2015 \"][\/et_pb_section]<\/p>\n

For reporting any side effects or safety information, please contact us directly via:
\nE-mail: drugsafetygcc@kyowakirin.com
\nHotline: +971 55 187 4456 | Landline: +971 4 581 3700 | Fax: +971 4 581 3776
\nPlease contact the relevant competent authority.[\/et_pb_accordion_item][et_pb_accordion_item title=”United Kingdom” icon_color=”#000000″ _builder_version=”4.25.1″ _module_preset=”default” body_text_color=”#FFFFFF” background_color=”#ea5504″ background_enable_color=”on” global_colors_info=”{}” toggle_text_color=”#FFFFFF” toggle_level=”h5″ toggle_font=”|700|||||||” open=”off”]<\/p>\n

UK Reporting and Contact form<\/strong><\/p>\n

\n
\n

Adverse events should be reported. Reporting forms and information can be found at https:\/\/yellowcard.mhra.gov.uk\/<\/a> or search MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported using the contact form below.<\/p>\n

\"\"<\/a><\/p>\n<\/div>\n<\/div>\n

[et_pb_section global_module=\"1930 \"][\/et_pb_section]<\/span><\/p>\n

\n
\n

Adverse events should also be reported to<\/span>
Kyowa Kirin on +44 (0)1896 664 000<\/span><\/h3>\n

<\/strong><\/p>\n<\/div>\n<\/div>\n

We are committed to an environment where open, honest communications are the expectation, not the exception. We encourage all who work or engage with us to report any matters of concern freely and openly at the earliest possible opportunity.<\/span>
To do so, we encourage you to use this Speak Up Line hosted by a third party provider, EthicsPoint. https:\/\/secure.ethicspoint.eu\/domain\/media\/en\/gui\/105727\/index.html<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][\/et_pb_accordion][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section” _builder_version=”4.24.3″ _module_preset=”default” background_color=”#5d6164″ custom_margin=”||||false|false” top_divider_style=”curve” top_divider_color=”#FFFFFF” top_divider_height=”71px” top_divider_repeat=”1x” top_divider_flip=”vertical” top_divider_style_tablet=”” top_divider_style_phone=”none” top_divider_style_last_edited=”on|desktop” saved_tabs=”all” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” width=”70%” max_width=”100%” custom_margin=”-50px||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/kyowakirininternational.com\/gcc-en\/wp-content\/uploads\/sites\/21\/2024\/01\/KKI-Logo-White-PhotoRoom-1-300×86.png” title_text=”KKI Logo White-PhotoRoom” align=”center” _builder_version=”4.24.0″ _module_preset=”default” width=”200px” width_tablet=”15%” width_phone=”50%” width_last_edited=”on|phone” module_alignment=”center” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_6,1_6,1_6″ _builder_version=”4.24.0″ _module_preset=”default” width=”70%” max_width=”100%” custom_padding=”||27px|||” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” width=”100%” max_width=”100%” custom_padding=”5px|10px|5px|10px|false|false” border_width_all=”1px” border_color_all=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

ADVERSE EVENTS SHOULD BE REPORTED HERE<\/a><\/span><\/p>\n

[\/et_pb_text][et_pb_text content_tablet=”” content_phone=”” content_last_edited=”on|phone” module_class=”my-popup2″ _builder_version=”4.25.1″ _module_preset=”default” text_font=”||||||||” text_text_color=”#E02B20″ text_orientation=”center” custom_margin=”||||false|false” custom_margin_tablet=”” custom_margin_phone=”-50px||||false|false” custom_margin_last_edited=”on|desktop” custom_padding=”||||false|false” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

Click here to search for Kyowa Kirin\u2019s clinical trials<\/a><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” text_font=”||||||||” text_text_color=”#FFFFFF” text_font_size=”16px” global_colors_info=”{}”]<\/p>\n

Press & Media<\/a><\/span>
Careers<\/a><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_text_color=”#FFFFFF” text_font_size=”16px” text_text_color_tablet=”” text_text_color_phone=”” text_text_color_last_edited=”on|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#FFFFFF”]<\/p>\n

Reporting<\/a><\/span>
Responsibility<\/a><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” width=”70%” max_width=”100%” custom_padding=”||27px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” header_6_text_color=”#FFFFFF” width=”100%” max_width=”100%” global_colors_info=”{}”]<\/p>\n

ABOUT US<\/a>\u00a0 |\u00a0 CONTACT US<\/a>\u00a0 |\u00a0 NOTICES<\/a>\u00a0 |\u00a0 TERMS OF USE<\/a><\/h4>\n

MODERN SLAVERY ACT<\/a> | THIRD PARTY CODE OF CONDUCT<\/a><\/h4>\n

KKI\/INT\/KKI\/0927 September 2024<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” width=”70%” max_width=”100%” custom_margin=”-50px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” text_text_color=”#FFFFFF” width=”100%” max_width=”100%” global_colors_info=”{}”]<\/p>\n

<\/span><\/p>\n

Copyright \u00a9 Kyowa Kirin International plc. All rights reserved. <\/span>This website is developed and funded by Kyowa Kirin International plc.<\/p>\n

Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels TD1 1QH, United Kingdom.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

REPORTING A SIDE EFFECT<\/p>\n

Kyowa Kirin takes patient safety seriously. We routinely monitor information from multiple sources regarding the safety of our products in order to take any necessary actions.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":27,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-1984","page","type-page","status-publish","hentry"],"yoast_head":"\nContact Us | Kyowa Kirin International<\/title>\n<meta name=\"description\" content=\"Stay informed on company updates, research, and developments. Access factual information related to our business and pharmaceutical products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Reporting\" \/>\n<meta property=\"og:description\" content=\"Stay informed on company updates, research, and developments. Access factual information related to our business and pharmaceutical products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/\" \/>\n<meta property=\"og:site_name\" content=\"Kyowa Kirin International - GCC\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-26T10:08:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kyowakirininternational.com\/gcc-en\/wp-content\/uploads\/sites\/21\/2024\/02\/Yellow-Card-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/\",\"url\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/\",\"name\":\"Contact Us | Kyowa Kirin International\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2024\\\/02\\\/Yellow-Card-1.png\",\"datePublished\":\"2024-04-01T12:02:16+00:00\",\"dateModified\":\"2024-09-26T10:08:29+00:00\",\"description\":\"Stay informed on company updates, research, and developments. Access factual information related to our business and pharmaceutical products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2024\\\/02\\\/Yellow-Card-1.png\",\"contentUrl\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2024\\\/02\\\/Yellow-Card-1.png\",\"width\":190,\"height\":71},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/global-reporting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Reporting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/#website\",\"url\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/\",\"name\":\"Kyowa Kirin International - GCC\",\"description\":\"A Specialty Pharmaceutical Company\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kyowakirininternational.com\\\/gcc-en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Contact Us | Kyowa Kirin International","description":"Stay informed on company updates, research, and developments. Access factual information related to our business and pharmaceutical products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/","og_locale":"en_GB","og_type":"article","og_title":"Global Reporting","og_description":"Stay informed on company updates, research, and developments. Access factual information related to our business and pharmaceutical products.","og_url":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/","og_site_name":"Kyowa Kirin International - GCC","article_modified_time":"2024-09-26T10:08:29+00:00","og_image":[{"url":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-content\/uploads\/sites\/21\/2024\/02\/Yellow-Card-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/","url":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/","name":"Contact Us | Kyowa Kirin International","isPartOf":{"@id":"https:\/\/kyowakirininternational.com\/gcc-en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/#primaryimage"},"image":{"@id":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/#primaryimage"},"thumbnailUrl":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-content\/uploads\/sites\/21\/2024\/02\/Yellow-Card-1.png","datePublished":"2024-04-01T12:02:16+00:00","dateModified":"2024-09-26T10:08:29+00:00","description":"Stay informed on company updates, research, and developments. Access factual information related to our business and pharmaceutical products.","breadcrumb":{"@id":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/#primaryimage","url":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-content\/uploads\/sites\/21\/2024\/02\/Yellow-Card-1.png","contentUrl":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-content\/uploads\/sites\/21\/2024\/02\/Yellow-Card-1.png","width":190,"height":71},{"@type":"BreadcrumbList","@id":"https:\/\/kyowakirininternational.com\/gcc-en\/global-reporting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kyowakirininternational.com\/gcc-en\/"},{"@type":"ListItem","position":2,"name":"Global Reporting"}]},{"@type":"WebSite","@id":"https:\/\/kyowakirininternational.com\/gcc-en\/#website","url":"https:\/\/kyowakirininternational.com\/gcc-en\/","name":"Kyowa Kirin International - GCC","description":"A Specialty Pharmaceutical Company","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kyowakirininternational.com\/gcc-en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/pages\/1984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/comments?post=1984"}],"version-history":[{"count":15,"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/pages\/1984\/revisions"}],"predecessor-version":[{"id":3403,"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/pages\/1984\/revisions\/3403"}],"wp:attachment":[{"href":"https:\/\/kyowakirininternational.com\/gcc-en\/wp-json\/wp\/v2\/media?parent=1984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}